ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) will host a R&D Webcast Presentation on Thursday, December 3 at 11:30 am ET. The webcast will be on the company’s website, http://www.isispharm.com/. A replay of the presentation will also be available on the site following the end of the event. For more information, contact Kristina Lemonidis (Investors) at 760.603.2490, or Amy Blackley, Ph.D (Media) at 760.603.2772.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
ISIS will also present at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 2. The company will begin its presentation at 10:30 am ET at the New York Palace Hotel. A webcast of the presentation will also be available on the company’s website.
Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company operates in a two principal segments: Drug Discovery and Development and Regulus Therapeutics Inc. Within the Drug Discovery and Development segment, its drug discovery platform enables the Company to identify drugs, providing potential targets to treat a range of diseases. As of December 31, 2008, the Company has 19 drugs in development. Its partners are licensed to develop, with the Company’s support, 15 of these 19 drugs. The Company and Alnylam established Regulus Therapeutics Inc. as a company focused on the discovery, development and commercialization of microRNA therapeutics. In January 2009, the Company sold its subsidiary, Ibis Biosciences, Inc. to Abbott Molecular Inc. (AMI), a wholly owned subsidiary of Abbott Laboratories.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
